Recce Pharmaceuticals Ltd (RCE:ASX)

$1.12

right-arrow Created with Sketch. -0.015 (-1.33%)
MCAP $193.5M
Last trade 16.10pm 27/11/2020 20mins delayed

Latest Announcements

26/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
23/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
10/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
10/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
10/11/2020RCERecce Pharmaceuticals Ltd
09/11/2020RCERecce Pharmaceuticals Ltd
05/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
03/11/2020 Price SensitivePSRCERecce Pharmaceuticals Ltd
21,413
MCap

Company Overview

Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

RCE in the news

Search Previous Announcements